Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2012
03/15/2012US20120065246 Rna molecules and therapeutic uses thereof
03/15/2012US20120065245 Regulation of hematopoietic stem cell functions through micrornas
03/15/2012US20120065242 POLYMERIC NANO-PARTICLES FOR siRNA DELIVERY USING CHARGE INTERACTION AND COVALENT BONDING
03/15/2012US20120065235 Compounds for treating proliferative disorders
03/15/2012US20120065233 Tyrosine kinase inhibitors
03/15/2012US20120065232 Photostabilization of retinoids with alkoxycrylene compounds
03/15/2012US20120065231 Thiophene derivative
03/15/2012US20120065230 Nitroxide Free Radical Synergized Antineoplastic Agents
03/15/2012US20120065227 TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
03/15/2012US20120065218 Heterocyclic Cyclopamine Analogs and Methods of Use Thereof
03/15/2012US20120065216 Quinazolinedione derivatives as parp inhibitors
03/15/2012US20120065213 C-met protein kinase inhibitors
03/15/2012US20120065210 Substituted hexahydropyrrolo[1,2-c]imidazolones
03/15/2012US20120065208 Cancer treatment
03/15/2012US20120065206 Compounds for treating proliferative disorders
03/15/2012US20120065202 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
03/15/2012US20120065201 Inhibitors of bruton's tyrosine kinase
03/15/2012US20120065199 Substituted quinolines for use as vegf inhibitors
03/15/2012US20120065192 N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors
03/15/2012US20120065191 Pharmaceutical compounds
03/15/2012US20120065185 Substituted alkylamine derivatives and methods of use
03/15/2012US20120065184 Compounds and compositions as trk inhibitors
03/15/2012US20120065183 Tetrahydro-Pyrido-Pyrimidine Derivatives
03/15/2012US20120065180 Androgen pharmaceutical composition and method for treating depression
03/15/2012US20120065173 Chemical compounds
03/15/2012US20120065172 Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
03/15/2012US20120065171 Fostriecin derivatives and the pharmaceutical uses thereof
03/15/2012US20120065161 Cyclodextrin-based polymers for therapeutic delivery
03/15/2012US20120065158 Fucoidan having antitumor activity
03/15/2012US20120065157 Particulate-soluble glucan preparation
03/15/2012US20120065154 Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof
03/15/2012US20120065153 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
03/15/2012US20120065151 Substances Mixture, Use and Infusion Solution
03/15/2012US20120065149 Vitamin receptor binding drug delivery conjugates
03/15/2012US20120065148 Phosphodiesterase 4d7 as prostate cancer marker
03/15/2012US20120065147 Use of the gtpase rab27b to diagnose and treat poor prognosis estrogen-receptor-positive breast cancer
03/15/2012US20120065146 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
03/15/2012US20120065145 Alkylating agent combinations in the treatment of cancer
03/15/2012US20120065144 Peptide for the Prophylactic or Therapeutic Treatment of Skin Tumors in Initial Stages
03/15/2012US20120065142 Novel solid materials of and methods for obtaining them
03/15/2012US20120065138 Lipids, lipid complexes and use thereof
03/15/2012US20120065134 Cd40-l inhibitory phylomer peptides
03/15/2012US20120065131 Compositions and methods for topical application and transdermal delivery of an oligopeptide
03/15/2012US20120065125 Methods and compositions for the treatment of cancer or other diseases
03/15/2012US20120065100 Phosphodiesterase 9a as prostate cancer marker
03/15/2012US20120064625 Nucleic Acids, Polypeptides, Compositions, and Methods for Modulating Apoptosis
03/15/2012US20120064600 Anti-5t4 antibodies and uses thereof
03/15/2012US20120064578 Chromosome-based platforms
03/15/2012US20120064571 Zcytor19 polynucleotides, polypeptides, antibodies and methods of use
03/15/2012US20120064179 Bicarbonate solution for bioavailable magnesium and uses thereof
03/15/2012US20120064178 Cell-8 Solution
03/15/2012US20120064175 HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients
03/15/2012US20120064163 Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
03/15/2012US20120064157 Pharmaceutical composition and administrations thereof
03/15/2012US20120064143 Inhibition of mammalian target of rapamycin
03/15/2012US20120064142 Polymeric pharmaceutical dosage form in sustained release
03/15/2012US20120064135 Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
03/15/2012US20120064124 Macrolide dosage forms
03/15/2012US20120064113 Novel Attenuated Poliovirus
03/15/2012US20120064111 Attenuated vaccines for non-segmented negative sense rna viruses
03/15/2012US20120064108 Glycoconjugate vaccines
03/15/2012US20120064107 Compositions and methods for treatment of autoimmune and other disease
03/15/2012US20120064102 Peptide inducing xage-1b-specific immune reaction and utilization of same
03/15/2012US20120064099 Compounds that inhibit nfkb and bace1 activity
03/15/2012US20120064096 BTLA Antibodies and Uses Thereof
03/15/2012US20120064090 Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
03/15/2012US20120064089 Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
03/15/2012US20120064083 Therapeutic use of anti-cs1 antibodies
03/15/2012US20120064081 Anti-kir3d antibodies
03/15/2012US20120064080 Human LY6-Big Molecules and Methods of Use
03/15/2012US20120064078 Novel Tumor Biomarket
03/15/2012US20120064072 Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
03/15/2012US20120064071 Treatment of cancer
03/15/2012US20120064069 Therapeutic use of anti-cs1 antibodies
03/15/2012US20120064068 Therapeutic use of anti-cs1 antibodies
03/15/2012US20120064067 Therapeutic use of anti-cs1 antibodies
03/15/2012US20120064066 Monoclonal Antibodies to Hepatocyte Growth Factor
03/15/2012US20120064062 Inhibitors of bacterial plasminogen activators
03/15/2012US20120064060 Compound having s1p receptor binding potency and use thereof
03/15/2012US20120064048 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
03/15/2012US20120064038 Epidermal growth factor receptor (egfr) and methods of use in adenoviral-associated virus type 6 (aav6) transduction
03/15/2012US20120064035 Vaccine immunotherapy
03/15/2012US20120064033 Modulation of regulatory t cells by human il-18
03/15/2012US20120064032 Novel hydroxamates as therapeutic agents
03/15/2012US20120064025 Quinazolinone Modulators Of Nuclear Receptors
03/15/2012US20120064008 Compositions for the treatment of metastatic cancer and methods of use thereof
03/15/2012US20120064004 Isotopologues of thalidomide
03/15/2012US20120064003 COMPLEX FOLATE-NOTA-Ga68
03/15/2012US20120064001 Anti-VEGF Antibody Compositions and Methods
03/15/2012US20120063999 Psca: prostate stem cell antigen and uses thereof
03/15/2012US20120063997 Delivery system with scaffolds
03/15/2012US20120063996 Novel nimesulide compositions
03/15/2012US20120063995 Non-ad5 adenoviral vectors and methods and uses related thereto
03/15/2012US20120063994 Rtef-1 variants and uses thereof
03/15/2012US20120063993 Therapeutic and diagnostic conjugates for use with multispecific antibodies
03/15/2012DE102010045185A1 Stoffgemisch, Verwendung und Infusionslösung Mixture, use and infusion
03/15/2012DE102010040705A1 Blütenextrakt von Primula flos zur Behandlung und Prophylaxe von Entzündungen oder viralen Infektionen Primula flower extract of flos for the treatment and prophylaxis of infections or viral infections
03/15/2012CA2810998A1 Inhibitors of human ezh2, and methods of use thereof
03/15/2012CA2810950A1 Sdf-1 binding nucleic acids and the use thereof in cancer treatment
03/15/2012CA2810838A1 Somatostatin receptor-based cancer therapy
1 ... 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 ... 2211